Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences ...
China approved Amgen’s tarlatamab for previously treated small cell lung cancer, expanding access to the bispecific immunotherapy. Amgen’s bispecific T-cell engager tarlatamab received regulatory ...
In this episode of Pharmaceutical Executive’s podcast series Leading Edge With Ken Banta, The Vanguard Network founder and ...
Distinct GLP1R and GIPR variants correlated with nausea/vomiting risk, with a GIPR signal appearing tirzepatide-specific and showing markedly increased vomiting odds. New studies from 23andMe suggest ...
GLP-1 drugs continue to dominate the pharmaceutical landscape. The medication is popular for its weight loss applications, and major pharmaceutical companies continue to introduce new versions of ...
In today's Pharmaceutical Executive Daily, China approves Amgen's tarlatamab for previously treated extensive-stage small cell lung cancer, a large study identifies genetic predictors of GLP-1 weight ...
Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences ...
Prior to assuming her current role at AstraZeneca, Sarin was CFO at Alexion. In December 2020, AstraZeneca acquired Alexion, ...
The U.S. government awarded Shionogi Inc. a contract worth up to $482 million to expand domestic manufacturing of Fetroja ...
Financially, the agreement includes a $20 million upfront payment to C4 Therapeutics, with the potential for additional ...
In today's Pharmaceutical Executive Daily, the Trump administration delays its appeal of the federal ruling blocking RFK ...
Pharmaceutical Executive: How does the complexity of obesity impact the effectiveness of GLP-1s? Mark Bagnall: This is one of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results